Payment overview · 2025
General Payments
$243.10
12 reported records · 6 companies
Healthcare provider profile · identity verified
Theodore G Rose, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GARDEN GROVE, CA · NPI 1629088281
Verified facts
What the public records show
CMS Open Payments records show Theodore G Rose, MD received $243.10 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $79.79 | 32.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.59 | 30.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.76 | 13.5% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $19.02 | 7.8% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.83 | 7.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.11 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.10 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $92.97 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.24 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 41 |
| Metformin Hcl | Metformin Hcl | 144 | 41 |
| Lisinopril | Lisinopril | 138 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 22 |
| Simvastatin | Simvastatin | 110 | 30 |
| Losartan Potassium | Losartan Potassium | 108 | 26 |
| Eliquis | Apixaban | 104 | 18 |
| Gabapentin | Gabapentin | 103 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 29 |
| Furosemide | Furosemide | 93 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 20 |
| Famotidine | Famotidine | 83 | 17 |
| Omeprazole | Omeprazole | 58 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 17 |
| Clonidine Hcl | Clonidine Hcl | 51 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Glipizide | Glipizide | 46 | 13 |
| Carvedilol | Carvedilol | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 17 |
| Levocarnitine | Levocarnitine (With Sugar) | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Baclofen | Baclofen | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 30 |
| Levalbuterol Hcl | Levalbuterol Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 14 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Monoject Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Nitro-Dur | Nitroglycerin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Techlite Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.10 · 12 records | Lilly USA, LLC | Cologuard Collection Kit, DUPIXENT, JARDIANCE, MOUNJARO, Ozempic, SMARTVEST, The Cologuard Plus Collection Kit, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error